Revolution Medicines, Inc.RVMD
Market cap
$14.7B
P/E ratio
| 2020/12 | 2021/12 | 2022/12 | 2023/12 | |
| Depreciation & amortization | 3 | 3 | 4 | - |
| Stock-based compensation | 9 | 21 | 31 | 62 |
| Cash from operations | -100 | -147 | -224 | -351 |
| Capital expenditures | -3 | -7 | -11 | -8 |
| Cash from investing | -234 | -142 | -24 | -343 |
| Cash from financing | 423 | 294 | 301 | 1,229 |
| Free cash flow | ||||
| FCF margin (%) |